Abstract Library

#3662 Nothing but NET? Neuroendocrine tumors in multiple endocrine neoplasia 4

Introduction: Multiple endocrine neoplasia 4 (MEN4) is a rare multi-neoplasia syndrome caused by a germline pathogenic variant in CDKN1B gene, encoding p27, a cell-cycle regulator. MEN4 manifestations include primary hyperparathyroidism (PHPT), pituitary adenomas (PitAd), and neuroendocrine neoplasms (NEN). The characteristics of MEN4-NENs have not been thoroughly characterized thus far.

Conference:

Presenting Author:

Authors: Halperin R, Arnon L, Nasirov S, Friedensohn L, Gershinsky M,

Keywords: MEN4, CDKN1B, lifetime risk, genotype-phenotype, multiple endocrine neoplasia,

#3471 A novel in vitro spheroid model enables multi-modality assessment of the anti-tumoral immune response in pancreatic neuroendocrine neoplasms

Introduction: Patients harbouring pancreatic neuroendocrine neoplasms (PNENs) often present as a non-resectable disease due to distant metastases, hence, efficacy of the current medical intervention is limited. Activation of the mammalian target of rapamycin (mTOR) pathway is a known tumorigenic driver in PNENs. mTOR inhibition by Everolimus (EVE) delays PNEN progression, but the mechanism is not clear. EVE is also used as an immunosuppressant, thus we hypothesized that it may suppress the anti-tumoral immune response.

Conference:

Presenting Author:

Authors: Nasirov S, Zaig E, Mor-Cohen R, Telerman A, Tirosh A,

Keywords: PNEN, spheroid, Everolimus, mTOR,